News & Events

• Seres Therapeutics Announces Completion of VOWST™ Asset Sale to Société des Produits Nestlé S.A
  Published on 2024-09-30
• Seres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30
  Published on 2024-09-26
• Seres Therapeutics to Participate in Cantor 2024 Global Healthcare Conference
  Published on 2024-09-13
• Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)
  Published on 2024-09-12
• Publication of Half-year report 2024
  Published on 2024-08-30
• Genetic Analysis AS: Publication of Half-year report 2024
  Published on 2024-08-30
• Genetic Analysis directed issue to major shareholders has now been registered with the Norwegian Register of Business Enterprises
  Published on 2024-08-14
• Seres Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates
  Published on 2024-08-13
• Genetic Analysis launches consumer microbiome testing platform through Prokarimi, powered by GA-map® technology
  Published on 2024-08-08
• Seres Therapeutics to Announce Second Quarter 2024 Financial Results and Business Update on August 13, 2024
  Published on 2024-08-06
• Seres Therapeutics Announces Signing of VOWST™ Asset Purchase Agreement with Nestlé Health Science
  Published on 2024-08-06
• Vedanta Biosciences Expands Leadership Team and Appoints Head of Commercial
  Published on 2024-07-23
• Minutes from the Extraordinary General Meeting 17 July 2024 in Genetic Analysis AS
  Published on 2024-07-17
• Genetic Analysis AS: Minutes from the Extraordinary General Meeting 17 July 2024
  Published on 2024-07-17
• Genetic Analysis: Direct issue has now been registered with the Norwegian Register of Business Enterprises
  Published on 2024-07-15